Stefan K. Barta, MD, MS

faculty photo
Associate Professor of Clinical Medicine
Department: Medicine

Contact information
Perelman Center
12th Floor, Room 12-177
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 2156156506
Fax: 2156155887
Education:
MD (Medicine)
Johann-Wolfgang Goethe University , 1999.
MS (Clinical Research Methods)
Albert Einstein College of Medicine , 2011.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Gerson James N, Handorf Elizabeth, Villa Diego, Gerrie Alina S, Chapani Parv, Li Shaoying, Medeiros L Jeffrey, Wang Michael I, Cohen Jonathon B, Calzada Oscar, Churnetski Michael C, Hill Brian T, Sawalha Yazeed, Hernandez-Ilizaliturri Francisco J, Kothari Shalin, Vose Julie M, Bast Martin A, Fenske Timothy S, Narayana Rao Gari Swapna, Maddocks Kami J, Bond David, Bachanova Veronika, Kolla Bhaskar, Chavez Julio, Shah Bijal, Lansigan Frederick, Burns Timothy F, Donovan Alexandra M, Wagner-Johnston Nina, Messmer Marcus, Mehta Amitkumar, Anderson Jennifer K, Reddy Nishitha, Kovach Alexandra E, Landsburg Daniel J, Glenn Martha, Inwards David J, Karmali Reem, Kaplan Jason B, Caimi Paolo F, Rajguru Saurabh, Evens Andrew, Klein Andreas, Umyarova Elvira, Pulluri Bhargavi, Amengual Jennifer E, Lue Jennifer K, Diefenbach Catherine, Fisher Richard I, Barta Stefan K: Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 37(6): JCO1800690, Jan 2019.

Barta Stefan K, Zain Jasmine, MacFarlane Alexander W, Smith Sonali M, Ruan Jia, Fung Henry C, Tan Carlyn R, Yang Yibin, Alpaugh R Katherine, Dulaimi Essel, Ross Eric A, Campbell Kerry S, Khan Nadia, Siddharta Rawat, Fowler Nathan H, Fisher Richard I, Oki Yasuhiro: Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clinical lymphoma, myeloma & leukemia Apr 2019.

Martin James M, Wu Hong, Barta Stefan K: CD30+ T-cell lymphoproliferative disorders. Chinese clinical oncology 8(1): 4, Oct 2018.

Badar Talha, Hamadani Mehdi, Bachanova Veronika, Maddocks Kami J, Umyarova Elvira, Chavez Julio C, Epperla Narendranath, Chhabra Saurabh, Xavier Ana C, Karmali Reem, Salhab Mohammed, Reddy Nishitha, Glenn Martha J, Hernandez-Ilizaliturri Francisco J, Flowers Christopher R, Evens Andrew M, Zhou Zheng, Lansigan Frederick, Barta Stefan K, Cohen Jonathon B, Fenske Timothy S, Costa Luciano J: Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leukemia & lymphoma 60(4): 1-7, Oct 2018.

Liu Yang, Barta Stefan Klaus: Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. American journal of hematology 94(5): 604-616, May 2019.

Tan CRC, Barta SK, Lee J, Rudek MA, Sparano JA, Noy A.: Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034. Leuk Lymphoma 59(8): 1851-1860, Aug 2018.

Reid Erin, Suneja Gita, Ambinder Richard F, Ard Kevin, Baiocchi Robert, Barta Stefan K, Carchman Evie, Cohen Adam, Gupta Neel, Johung Kimberly L, Klopp Ann, LaCasce Ann S, Lin Chi, Makarova-Rusher Oxana V, Mehta Amitkumar, Menon Manoj P, Morgan David, Nathwani Nitya, Noy Ariela, Palella Frank, Ratner Lee, Rizza Stacey, Rudek Michelle A, Taylor Jeff, Tomlinson Benjamin, Wang Chia-Ching J, Dwyer Mary A, Freedman-Cass Deborah A: Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 16(8): 986-1017, Aug 2018.

Tan CRC, Abdul-Majeed S, Cael B, Barta SK.: Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. Clin Pharmacokinet 58(2): 157-168, May 26 2018 Notes: [Epub ahead of print] doi: 10.1007/s40262-018-0679-9.

Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H.: NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. J Natl Compr Canc Netw 16(2): 123-135, Feb 2018.

Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang M, Cohen JB, Calzada O, Churnetski M, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast M, Fenske TM, Rao Gari SN, Maddocks KJ, Bond D, Bachanova V, Lansigan F, Burns T, Donovan AD, Mehta A, Anderson JK, Reddy N, Kovach A, Landsburg DJ, Glenn M, Inwards DJ, Ristow K, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach D, Evens A, Klein A, Barta SK. : Consolidation with Autologous Hematopoietic Cell Transplant in First Remission Improves Overall Survival in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era. American Society of Hematology Annual Meeting, San Francisco, CA Dec 2017 Notes: Abstract 341. "Poster Presentation"

Barta SK, Jain R, Mazumder A, Carter J, Almanzar L, Browne R, Shahnaz S, Elkind R, Kaminetzky D, Battini R, Derman O, Kornblum N, Verma A, Braunschweig I.: Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 17(10): 650-657, Oct 2017.

Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Colocci N, Bengtson EM, Horning SJ, Kahl BS.: Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer. 122(19): 2996-3004, Oct 2016.

Ratner L, Rauch D, Abel H, Caruso B, Noy A, Barta SK, Parekh S, Ramos JC, Ambinder R, Phillips A, Harding J, Baydoun HH, Cheng X, Jacobson S.: Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood Cancer J. 25(6): e408, Mar 2016.

Landsburg DJ, Ramchandren R, Oki Y, Pagel JM, Lugtennurg PJ, Gharavi R, Ma A, Hafeez A, Barta SK. : Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907. American Society of Hematology Annual Meeting, San Francisco, CA Dec 2017 Notes: Abstract 1555. "Poster Presentation"

back to top
Last updated: 05/31/2019
The Trustees of the University of Pennsylvania